Navigation Links
PDL BioPharma Announces Retirement of $54.3 Million of 2.75% Convertible Notes Due 2023
Date:9/16/2010

INCLINE VILLAGE, Nev., Sept. 16 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the retirement of the remaining $54.3 million in aggregate principal of the Company's 2.75% Convertible Subordinated Notes, due August 16, 2023 (the "2023 Notes") in exchange for 8.9 million shares of common stock and $4.2 million in cash.  With the completion of this redemption, no 2023 Notes remain outstanding.

In accordance with the terms of the 2023 Notes, the Company previously issued a redemption notice to redeem the 2023 Notes at a redemption price of 100% of the outstanding principal amount, together with accrued and unpaid interest to, but excluding, the redemption date of September 15, 2010.  Note holders could elect to convert their 2023 Notes into the Company's common stock on or before September 14, 2010.  Accordingly, note holders elected to convert $50.1 million of 2023 Notes into 8.9 shares of common stock at the existing conversion price equivalent to $5.64 per share.  With the retirement of the 2023 Notes, the Company has 139.7 million shares of common stock outstanding.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today based on patents that expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Diaceutics and London Genetics Partner to Accelerate Biomarker Development in the Global Biopharmaceutical Industry
2. FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
3. PDL BioPharma Receives Letter from Genentech Relating to European Patents
4. CeNeRx BioPharma Completes $13 Million Series C Financing
5. Almac Launch Biomarkers for Biopharma
6. Health Outcomes Data Essential to Biopharmaceutical Sales Process
7. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
8. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
9. Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences
10. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
11. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):